Tectonic Therapeutic Inc
TECX21.030USD
+0.300+1.45%
시장 운영 시간 （ET）시세는 15분 지연됩니다
392.66M시가총액
손실P/E TTM
자세한 내용은 Tectonic Therapeutic Inc 회사
Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead program, TX000045 (TX45), is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). Its second program addresses Hereditary Hemorrhagic Telangiectasia (HHT).
회사 정보
종목 코드 TECX
회사 이름Tectonic Therapeutic Inc
상장일Jun 21, 2018
CEODr. Alise S. Reicin, M.D.
직원 수51
유형Ordinary Share
회계 연도 종료Jun 21
주소490 Arsenal Way
도시WATERTOWN
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호02472
전화13396663320
웹사이트https://tectonictx.com/
종목 코드 TECX
상장일Jun 21, 2018
CEODr. Alise S. Reicin, M.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.25K
-0.30%
Dr. Peter Mcnamara, Ph.D.
Dr. Peter Mcnamara, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.53K
+344.82%
Dr. Praveen P. Tipirneni, M.D.
Dr. Praveen P. Tipirneni, M.D.
Independent Director
Independent Director
3.04K
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Lochner
Mr. Daniel Lochner
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Terrance G. (Terry) Mcguire
Mr. Terrance G. (Terry) Mcguire
Independent Director
Independent Director
--
--
Dr. Marc Schwabish, Ph.D.
Dr. Marc Schwabish, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Phillip B. (Phil) Donenberg
Mr. Phillip B. (Phil) Donenberg
Independent Director
Independent Director
--
--
Mr. Stefan Vitorovic
Mr. Stefan Vitorovic
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.25K
-0.30%
Dr. Peter Mcnamara, Ph.D.
Dr. Peter Mcnamara, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.53K
+344.82%
Dr. Praveen P. Tipirneni, M.D.
Dr. Praveen P. Tipirneni, M.D.
Independent Director
Independent Director
3.04K
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Lochner
Mr. Daniel Lochner
Chief Financial Officer
Chief Financial Officer
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Tue, Jul 22
마지막 업데이트: Tue, Jul 22
주주
주주 유형
주주
주주
비율
Springer Timothy A
23.68%
Fidelity Management & Research Company LLC
14.99%
Deep Track Capital LP
7.51%
TAS Partners, L.L.C.
7.41%
EcoR1 Capital, LLC
5.01%
Other
41.40%
주주
주주
비율
Springer Timothy A
23.68%
Fidelity Management & Research Company LLC
14.99%
Deep Track Capital LP
7.51%
TAS Partners, L.L.C.
7.41%
EcoR1 Capital, LLC
5.01%
Other
41.40%
주주 유형
주주
비율
Individual Investor
27.37%
Hedge Fund
24.98%
Investment Advisor
22.57%
Corporation
10.93%
Investment Advisor/Hedge Fund
7.56%
Venture Capital
2.74%
Research Firm
2.25%
Pension Fund
0.12%
Family Office
0.05%
Other
1.43%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
178
18.44M
98.77%
+1.52M
2025Q1
184
18.15M
106.94%
+1.93M
2024Q4
153
13.88M
94.13%
+369.61K
2024Q3
148
13.13M
89.69%
+166.42K
2024Q2
151
11.92M
81.47%
+8.19M
2024Q1
179
2.57M
67.87%
-1.12M
2023Q4
200
2.14M
56.67%
-1.83M
2023Q3
236
2.28M
60.58%
-1.25M
2023Q2
243
1.76M
47.84%
-1.94M
2023Q1
262
2.00M
54.58%
-1.52M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Springer Timothy A
4.42M
23.68%
+196.29K
+4.64%
Apr 11, 2025
Fidelity Management & Research Company LLC
2.80M
14.99%
+1.28M
+84.63%
Mar 31, 2025
Deep Track Capital LP
1.40M
7.51%
--
--
Mar 31, 2025
TAS Partners, L.L.C.
1.38M
7.41%
+412.50K
+42.52%
Apr 03, 2025
EcoR1 Capital, LLC
935.12K
5.01%
+85.98K
+10.13%
Mar 31, 2025
Farallon Capital Management, L.L.C.
853.05K
4.57%
+140.00K
+19.63%
Mar 31, 2025
Polaris Partners
657.98K
3.52%
-500.00K
-43.18%
Apr 03, 2025
5AM Ventures
511.66K
2.74%
-85.00K
-14.25%
Mar 31, 2025
Prosight Capital
398.88K
2.14%
+398.88K
--
Mar 31, 2025
The Vanguard Group, Inc.
361.17K
1.93%
+120.00
+0.03%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.02%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
더 보기
Virtus LifeSci Biotech Clinical Trials ETF
비율0.8%
iShares Micro-Cap ETF
비율0.05%
Invesco Nasdaq Biotechnology ETF
비율0.04%
ProShares Ultra Nasdaq Biotechnology
비율0.04%
iShares Biotechnology ETF
비율0.02%
Global X Russell 2000 ETF
비율0.01%
ProShares Hedge Replication ETF
비율0.01%
iShares Russell 2000 Value ETF
비율0.01%
iShares Russell 2000 ETF
비율0.01%
Proshares Ultra Russell 2000
비율0.01%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
날짜
유형
비율
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
